Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE- FDA Decision: Beam Therapeutics (BEAM)

The Phase 3 date for Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE- by Beam Therapeutics (BEAM) is scheduled for July 31, 2028. This is the target date for the FDA to make a decision on this application.

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE- is being developed by Beam Therapeutics for the treatment of its target indication. It is currently in Phase 3 clinical trials.

If Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE- receives FDA approval, Beam Therapeutics (BEAM) would be able to market the drug in the United States for its target indication. This typically leads to significant stock price movement for biotech companies. Investors should monitor the Phase 3 date closely.

Biotech companies often raise capital through share offerings, which can dilute existing shareholders. You can check the current dilution risk for BEAM on DilutionWatch at dilutionwatch.com/stock/BEAM.html.

You can view the full BiotechSigns company profile for Beam Therapeutics (BEAM) at biotechsign.com/app/company/BEAM, which includes the BTS Score, signal history, clinical trial data, and insider trading activity.